Published in Neurology on December 01, 1992
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A (1996) 2.10
Manganese inhibits mitochondrial aconitase: a mechanism of manganese neurotoxicity. Brain Res (1998) 1.84
Understanding the human health effects of chemical mixtures. Environ Health Perspect (2002) 1.83
Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J (2006) 1.78
Alteration of iron homeostasis following chronic exposure to manganese in rats. Brain Res (1999) 1.68
Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry (1995) 1.65
Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord (2012) 1.49
Differential cytotoxicity of Mn(II) and Mn(III): special reference to mitochondrial [Fe-S] containing enzymes. Toxicol Appl Pharmacol (2001) 1.35
Toxicology of choroid plexus: special reference to metal-induced neurotoxicities. Microsc Res Tech (2001) 1.24
Iron overload following manganese exposure in cultured neuronal, but not neuroglial cells. Brain Res (2001) 1.21
Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm (Vienna) (1997) 1.18
Neurotoxicology of the brain barrier system: new implications. J Toxicol Clin Toxicol (2001) 1.09
Idiopathic Parkinson's disease: epidemiology, diagnosis and management. Br J Gen Pract (1995) 1.03
The promise of neuroprotective agents in Parkinson's disease. Front Neurol (2011) 0.96
Oxygen toxicity induces apoptosis in neuronal cells. Cell Mol Neurobiol (1998) 0.94
Frequency of the apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease. J Neurol Neurosurg Psychiatry (1996) 0.91
Up-regulation of gamma-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson's disease. Free Radic Biol Med (2006) 0.89
Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry (1994) 0.89
Nicotinamide nucleotide transhydrogenase (Nnt) links the substrate requirement in brain mitochondria for hydrogen peroxide removal to the thioredoxin/peroxiredoxin (Trx/Prx) system. J Biol Chem (2014) 0.88
Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm (Vienna) (1997) 0.83
Loss of non-phosphorylated neurofilament immunoreactivity, with preservation of tyrosine hydroxylase, in surviving substantia nigra neurons in Parkinson's disease. J Neurol Neurosurg Psychiatry (1994) 0.78
Selenoprotein T Exerts an Essential Oxidoreductase Activity That Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease. Antioxid Redox Signal (2016) 0.75
Corticocortical inhibition in human motor cortex. J Physiol (1993) 8.92
Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72
Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. J Physiol (1989) 5.69
Servo action in the human thumb. J Physiol (1976) 4.93
Interhemispheric inhibition of the human motor cortex. J Physiol (1992) 4.77
Servo action in human voluntary movement. Nature (1972) 4.33
Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Painful legs and moving toes. Brain (1971) 3.63
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain (1994) 3.54
Writers' cramp-a focal dystonia. Brain (1982) 3.43
Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ (1998) 3.41
Outcome of investigation of patients with presenile dementia. Br Med J (1972) 3.39
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet (1992) 3.30
Stretch reflex and servo action in a variety of human muscles. J Physiol (1976) 3.29
Scope of a technique for electrical stimulation of human brain, spinal cord, and muscle. Lancet (1982) 3.26
The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology (1982) 3.26
Corticobasal degeneration. Brain (1989) 3.20
Stimulation of the human motor cortex through the scalp. Exp Physiol (1991) 3.16
Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci (1967) 2.97
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med (1980) 2.81
Motor cortex stimulation in intact man. 2. Multiple descending volleys. Brain (1987) 2.77
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76
Classification of dystonia. Adv Neurol (1998) 2.75
Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1988) 2.74
Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry (1976) 2.72
Human walking and higher-level gait disorders, particularly in the elderly. Neurology (1993) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64
Manual motor performance in a deafferented man. Brain (1982) 2.63
The anatomical basis of symptomatic hemidystonia. Brain (1985) 2.60
Is the human stretch reflex cortical rather than spinal? Lancet (1973) 2.58
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (1976) 2.54
Movement disorders in multiple sclerosis. Mov Disord (1995) 2.53
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
The pathophysiology of primary dystonia. Brain (1998) 2.51
Pathophysiology of blepharospasm and oromandibular dystonia. Brain (1985) 2.50
A method of monitoring function in corticospinal pathways during scoliosis surgery with a note on motor conduction velocities. J Neurol Neurosurg Psychiatry (1986) 2.50
Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry (1988) 2.46
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Changes in the response to magnetic and electrical stimulation of the motor cortex following muscle stretch in man. J Physiol (1991) 2.44
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Attitudes of families to some aspects of Huntington's chorea. Psychol Med (1979) 2.40
A study of hereditary essential tremor. Brain (1994) 2.37
Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry (1986) 2.37
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain (1988) 2.36
Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology (1992) 2.36
Disturbance of sequential movements in patients with Parkinson's disease. Brain (1987) 2.30
Postural electromyographic responses in the arm and leg following galvanic vestibular stimulation in man. Exp Brain Res (1993) 2.30
Abnormalities in central motor pathway conduction in multiple sclerosis. Lancet (1984) 2.30
Isolated single motor units in human muscle and their rate of discharge during maximal voluntary effort. J Physiol (1971) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22
Delay in the execution of voluntary movement by electrical or magnetic brain stimulation in intact man. Evidence for the storage of motor programs in the brain. Brain (1989) 2.19
The sensory mechanism of servo action in human muscle. J Physiol (1977) 2.18
Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatry (1976) 2.18
Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet (1997) 2.16
Hysteria--a neurologist's view. Psychol Med (1986) 2.12
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem (1997) 2.10
Corticobasal degeneration. A clinical study of 36 cases. Brain (1994) 2.10
Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol (1996) 2.09
'Subcortical dementia': the neuropsychological evidence. Neuroscience (1988) 2.08
Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain (1995) 2.06
Ballistic flexion movements of the human thumb. J Physiol (1979) 2.06
Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy. Mov Disord (2000) 2.06
Reciprocal inhibition between the muscles of the human forearm. J Physiol (1984) 2.05
Relationship between plasma propranolol concentration and relief of essential tremor. J Neurol Neurosurg Psychiatry (1979) 2.04
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Modulation of motor cortical excitability by electrical stimulation over the cerebellum in man. J Physiol (1991) 2.01
Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res (1995) 1.98
Motor cortex stimulation in intact man. 1. General characteristics of EMG responses in different muscles. Brain (1987) 1.98
Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet (1977) 1.96
Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet (1994) 1.95
Performance of simultaneous movements in patients with Parkinson's disease. Brain (1986) 1.95
Idiopathic torsion dystonia (dystonia musculorum deformans). A review of forty-two patients. Brain (1974) 1.93
Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents. Psychopharmacologia (1975) 1.93
How common is dementia in Parkinson's disease? Lancet (1984) 1.93
Percutaneous electrical stimulation of corticospinal pathways at the level of the pyramidal decussation in humans. Ann Neurol (1991) 1.93
Assessing tremor severity. J Neurol Neurosurg Psychiatry (1993) 1.92
Effect of vision and stance width on human body motion when standing: implications for afferent control of lateral sway. J Physiol (1993) 1.91
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Mitochondrial myopathies: clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Ann Neurol (1989) 1.88
Scaling of the size of the first agonist EMG burst during rapid wrist movements in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (1986) 1.88
Assessment of extrapyramidal disorders. Br J Clin Pharmacol (1981) 1.86
Movement disorders following lesions of the thalamus or subthalamic region. Mov Disord (1994) 1.86
A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet (1973) 1.85
Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry (1986) 1.84
Different sites of action of electrical and magnetic stimulation of the human brain. Neurosci Lett (1987) 1.84
Mitochondria and degenerative disorders. Am J Med Genet (2001) 1.81
Botulinum toxin treatment of spasmodic torticollis. J R Soc Med (1992) 1.81
New observations on the normal auditory startle reflex in man. Brain (1991) 1.80
The stiff leg syndrome. J Neurol Neurosurg Psychiatry (1997) 1.80
Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry (1977) 1.79